A COST-UTILITY ANALYSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN THE NETHERLANDS: REDUCED HYPOPHOSPHATEMIA AND FRACTURE INCIDENCE WITH FERRIC DERISOMALTOSE VERSUS FERRIC

被引：0

作者：

Oron, U. ^{[1
]}

Koek, G. ^{[2
]}

Fijn, R. ^{[3
]}

Pollock, R. ^{[4
]}

机构：

[1] C3 Consultancy Cooperat, Egmond Aan Zee, Netherlands

[2] Maastricht Univ, Med Ctr, Maastricht, Limburg, Netherlands

[3] Alrijne Healthcare Grp, Leiden, South Holland, Netherlands

[4] Covalence Res Ltd, Harpenden, Herts, England

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE314

引用

页码：S116 / S116

页数：1

共 50 条

[1] Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
Iqbal, Tariq H.
Kennedy, Nicholas
Dhar, Anjan
Ahmed, Waqas
Pollock, Richard F.
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 392 - 403
[2] A UK COST-UTILITY ANALYSIS OF FERRIC CARBOXYMALTOSE VERSUS FERRIC DERISOMALTOSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA AND INFLAMMATORY BOWEL DISEASE: INCORPORATION OF FRACTURE DATA
Zoller, H.
Pammer, L. M.
Nottmeier, M.
Poehlmann, J.
Pollock, R. F.
VALUE IN HEALTH, 2024, 27 (06) : S69 - S70
[3] A SWEDISH COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Lindgren, S.
Pollock, R.
VALUE IN HEALTH, 2023, 26 (12) : S162 - S162
[4] COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN TREATING IRON DEFICIENCY ANEMIA IN NORWEGIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Detlie, T. E.
Karlsen, L. N.
Pollock, R.
VALUE IN HEALTH, 2023, 26 (12) : S131 - S131
[5] A cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Finland
Metsarinne, K.
Saavuori, N.
Ahmed, W.
Pollock-Wilkins, R.
Salminen, K.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1885 - I1886
[6] A COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA IN CHINA
Zhang, F.
Shen, A.
Ahmed, W.
Pollock, R.
VALUE IN HEALTH, 2023, 26 (12) : S102 - S103
[7] A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China
Zhang, Fengkui
Shen, Aizong
Ahmed, Waqas
Pollock, Richard F.
ADVANCES IN THERAPY, 2024, 41 (11) : 4191 - 4204
[8] An Australian cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease: implications of incorporating fracture incidence
Khalafallah, Alhossain
Abel, Sean
Pollock, Richard
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 251 - 251
[9] Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway
Detlie, T. E.
Karlsen, L. N.
Jorgensen, E.
Nanu, N.
Pollock, R. F.
JOURNAL OF MEDICAL ECONOMICS, 2025, 28 (01) : 291 - 301
[10] A COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN ITALY
Cortesi, P.
Mazzaglia, G.
Rethmeier, L.
Nottmeier, M.
Pollock, R. F.
VALUE IN HEALTH, 2022, 25 (12) : S103 - S103

← 1 2 3 4 5 →